Medistim ASA is a leading medical technology company specializing in intraoperative blood flow measurement technologies. With a strong focus on innovation, quality, and patient safety, Medistim ASA is committed to providing healthcare professionals with cutting-edge solutions to improve surgical outcomes. The company's corporate philosophy revolves around the values of integrity, collaboration, and excellence, fostering strong partnerships with healthcare providers worldwide. Medistim ASA is dedicated to advancing medical knowledge, optimizing patient care, and continuously enhancing its products and services to meet the evolving needs of the healthcare industry.

Medistim ASA is primarily present in Norway, where its headquarters are located, as well as in several other countries and regions worldwide. The company has established a strong international presence, with a significant presence in the United States, Europe, and Asia. Medistim ASA's innovative medical technology solutions are used by healthcare professionals in various countries to enhance surgical procedures and improve patient outcomes.

Medistim ASA has achieved significant milestones throughout its history. One notable milestone is the development of its innovative surgical navigation and ultrasound technology, allowing for real-time intraoperative blood flow analysis. Another significant achievement includes the successful introduction of Medistim's products in key markets worldwide, expanding its global presence. The company has also made strides in enhancing its product portfolio with new releases, such as VeriQC system and VeriQ Flowwire. Additionally, Medistim ASA has received various awards and recognitions for its dedication to innovative medical technology solutions. These milestones highlight Medistim ASA's commitment to advancing surgical procedures and improving patient outcomes.

Medistim ASA is a leading medical technology company based in Norway. Founded in 1984, Medistim specializes in developing and commercializing innovative products for intraoperative quality assurance in cardiac and vascular surgeries. With over three decades of expertise, the company has established itself as a global provider of high-quality surgical solutions. Medistim's focus on improving patient outcomes and reducing healthcare costs has earned it a strong reputation in the industry. As a recognized leader in surgical imaging and Doppler technology, Medistim remains committed to advancing medical practices through continuous research and development. The company's dedication to innovation and exceptional product quality has propelled its growth and global presence.

The main competitors of Medistim ASA in the market are companies like Teleflex Incorporated, Edwards Lifesciences Corporation, Transonic Systems Inc., and Lombard Medical Technologies.

Medistim ASA is primarily active in the medical industry, specifically in the field of medical technology. The company specializes in developing and manufacturing innovative solutions for intraoperative blood flow measurement and quality assessment during surgical procedures. Medistim's products are widely used in various surgical specialties, including cardiac, vascular, and transplant surgeries. With its advanced technologies and reliable devices, Medistim plays a crucial role in improving patient outcomes and enhancing surgical efficiency.

Medistim ASA, a leading medical technology company, operates with a business model focused on improving surgical outcomes through its innovative products and services. The company primarily specializes in developing and providing high-quality medical devices for use in surgical procedures, specifically within the fields of cardiovascular and transplant surgeries. Medistim's flagship product, the VeriQ system, enables surgeons to accurately measure and monitor blood flow during procedures, enhancing patient safety and surgical precision. By offering cutting-edge solutions, Medistim ASA aims to support medical professionals in optimizing surgical outcomes and ultimately improving patient health and wellbeing.

The P/E ratio cannot be calculated for Medistim A at the moment.

The P/S cannot be calculated for Medistim A currently.

The Quality Investing for Medistim A is 9/10.

The expected Medistim A revenue is 572.22 M NOK.

The expected Medistim A profit is 112.24 M NOK.

Medistim ASA is a leading provider of highly effective medical instruments and systems used in the diagnosis, monitoring, and treatment of vascular diseases. The Norwegian company's business model is based on a wide range of products organized into three core divisions: Vascular Surgery, Cardiac Surgery, and Cardiology. The Vascular Surgery division includes products specifically designed for the treatment of vascular diseases, such as ultrasound systems that provide high-resolution and precise imaging of arterial and venous vessels to support vascular surgery. The Cardiac Surgery division focuses on products used in the surgical treatment of heart diseases, including instruments and systems used during heart surgeries, such as ultrasound Doppler probes for monitoring blood flow and navigation systems for accurate placement of heart valves. The Cardiology division offers a variety of products used in non-invasive diagnosis and treatment of heart diseases, such as EKG devices for measuring heart electrical activity and ultrasound systems for examining heart structure and function. Medistim ASA's business model also includes close collaboration with clinics and medical research institutions to better understand customer needs and react to market changes. The company aims to continuously develop and improve its products to expand its market position and provide maximum value to customers. In summary, Medistim ASA's business model is based on a wide product range and close exchange with customers and research institutions. The company's products are used in various areas of medicine, contributing to early disease detection and improving diagnosis and patient treatment. With a strong focus on research and development and a dedicated team of employees, Medistim ASA aims to continue playing an important role in the market for medical devices and systems.

Medistim A pays a dividend of 3.75 NOK distributed over payouts per year.

The dividend cannot currently be calculated for Medistim A or the company does not pay out a dividend.

The ISIN of Medistim A is NO0010159684.

The WKN of Medistim A is A0D9B1.

The ticker of Medistim A is MEDI.OL.

Over the past 12 months, Medistim A paid a dividend of 4.5 NOK . This corresponds to a dividend yield of about . For the coming 12 months, Medistim A is expected to pay a dividend of 5.02 NOK.

The current dividend yield of Medistim A is .

Medistim A pays a quarterly dividend. This is distributed in the months of May, May, May, May.

Medistim A paid dividends every year for the past 22 years.

For the upcoming 12 months, dividends amounting to 5.02 NOK are expected. This corresponds to a dividend yield of 3.18 %.

Medistim A is assigned to the 'Health' sector.

To receive the latest dividend of Medistim A from 5/1/2024 amounting to 4.5 NOK, you needed to have the stock in your portfolio before the ex-date on 4/25/2024.

The last dividend was paid out on 5/1/2024.

In the year 2024, Medistim A distributed 4.5 NOK as dividends.

The dividends of Medistim A are distributed in NOK.